接受托法替布治疗的急性重度溃疡性结肠炎患者行结肠切除术后的结局
这项多中心回顾性病例对照研究比较了托法替布与英夫利西单抗治疗的急性重度溃疡性结肠炎(ASUC)患者结肠切除术后的结局。英夫利西单抗组总体并发症(64.7% vs 31.7%,P=.002)和严重并发症(27.9% vs 12%,P=.019)发生率均高于托法替布组。多变量分析中,托法替布组总体并发症发生率显著更低(OR 0.38,95%CI 0.16-0.87,P=.023),严重并发症风险无显著差异(OR 0.28,95%CI 0.06-0.96,P=.061)。
要点
- 英夫利西单抗组总体术后并发症率64.7%,高于托法替布组的31.7%(P=.002)。
- 英夫利西单抗组严重术后并发症率27.9%,高于托法替布组的12%(P=.019)。
- 多变量分析中托法替布组总体并发症OR 0.38(95%CI 0.16-0.87,P=.023)。
核心结论
- 接受托法替布治疗的ASUC患者总体术后并发症发生率显著低于英夫利西单抗治疗者,但严重术后并发症风险无显著差异。
- 作者指出需要更大规模的前瞻性试验来证实这些发现。
研究设计与样本
- 多中心、回顾性、病例对照研究,纳入因ASUC住院并接受结肠切除术的患者。
- 比较结肠切除术前接受托法替布治疗的患者(41例)与接受英夫利西单抗治疗的对照(68例)。
- 主要结局为结肠切除术后30天内严重术后并发症发生率。
- 采用多变量回归比较两组结局,校正开放手术和累积糖皮质激素暴露。
主要发现
- 英夫利西单抗组总体术后并发症44例(64.7%),托法替布组13例(31.7%)(P=.002)。
- 英夫利西单抗组严重术后并发症19例(27.9%),托法替布组3例(12%)(P=.019)。
- 多变量分析中,托法替布组严重术后并发症风险无显著差异(OR 0.28,95%CI 0.06-0.96,P=.061)。
- 多变量分析中,托法替布组总体术后并发症发生率显著更低(OR 0.38,95%CI 0.16-0.87,P=.023)。
关键数值与推荐
- 主要结局为结肠切除术后30天内严重术后并发症发生率。
- 严重术后并发症多变量分析:OR 0.28(95%CI 0.06-0.96,P=.061),未达统计学显著。
- 总体术后并发症多变量分析:OR 0.38(95%CI 0.16-0.87,P=.023)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要更大规模的前瞻性试验来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Up to 30% of patients with acute severe ulcerative colitis (ASUC) will require urgent colectomy despite initiation of intravenous corticosteroids and rescue therapies. Janus kinase inhibitors, such as tofacitinib, have emerged as an effective agent for ASUC; however, there are currently limited data evaluating the risk of postoperative complications among patients who received tofacitinib treatment for an episode of ASUC compared with infliximab. METHODS: We conducted a multicenter, retrospective, case-control study of patients hospitalized with ASUC who underwent colectomy, comparing patients treated with tofacitinib prior to colectomy with infliximab-treated controls. The primary outcome was rate of serious postoperative complications within 30 days of colectomy. Outcomes were compared between the tofacitinib-treated cases and infliximab-treated controls using multivariable regression adjusted for open surgery and cumulative corticosteroid exposure. RESULTS: Forty-one tofacitinib-treated patients were compared with 68 infliximab-treated patients with ASUC. Compared with tofacitinib-treated patients, infliximab-treated patients had higher overall rates of overall (44 [64.7%] vs 13 [31.7%]; P = .002) and serious (19 [27.9%] vs 3 [12%]; P = .019) postoperative complications. No significant different risk for developing serious postoperative complications (odds ratio, 0.28; 95% confidence interval, 0.06-0.96; P = .061) was observed in multivariable analysis; however, a significantly lower rate of overall postoperative complications (odds ratio, 0.38; 95% confidence interval, 0.16-0.87; P = .023) was observed in tofacitinib-treated patients compared with infliximab-treated patients. CONCLUSIONS: We observed a significantly lower rate of overall postoperative complications in ASUC patients treated with tofacitinib compared with infliximab; however, no difference was observed in the risk for serious postoperative complications. Larger prospective trials are needed to confirm these findings.
引用
- Larson C, Berinstein JA, Tedesco N, et al. Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing Colectomy. Clin Gastroenterol Hepatol. 2025. PMID: 40239733. doi:10.1016/j.cgh.2025.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。